The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
Open accessAbstract
GLP-1 (glucagon-like peptide-1) is an incretin released from intestinal L-cells in response to food intake. Activation of the GLP-1 receptor potentiates the synthesis and release of insulin from pancreatic beta-cells in a glucose-dependent manner. The GLP-1 receptor belongs to class B of the G-protein-coupled receptors, a subfamily characterized by a large N-terminal extracellular ligand binding domain. Exendin-4 and GLP-1 are 50% identical, and exendin-4 is a full agonist with similar affinity and potency for the GLP-1 receptor. We recently solved the crystal structure of the GLP-1 receptor extracellular domain in complex with the competitive antagonist exendin-4(9-39). Interestingly, the isolated extracellular domain binds exendin-4 with much higher affinity than the endogenous agonist GLP-1. Here, we have solved the crystal structure of the extracellular domain in complex with GLP-1 to 2.1 Aresolution. The structure shows that important hydrophobic ligand-receptor interactions are conserved in agonist- and antagonist-bound forms of the extracellular domain, but certain residues in the ligand-binding site adopt a GLP-1-specific conformation. GLP-1 is a kinked but continuous alpha-helix from Thr(13) to Val(33) when bound to the extracellular domain. We supplemented the crystal structure with site-directed mutagenesis to link the structural information of the isolated extracellular domain with the binding properties of the full-length receptor. The data support the existence of differences in the binding modes of GLP-1 and exendin-4 on the full-length GLP-1 receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
Kabsch, W. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889893005588 · Cited by 3,578
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Self-citationCryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M., Qu, Q., Tarrasch, J. T., Li, S., Sun Kobilka, T., Kobilka, B. K., et al. (2017) · Nature · doi:10.1038/nature22394 · Cited by 576
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Structure of the human glucagon class B G-protein-coupled receptor
Siu, F. Y., He, M., de Graaf, C., Han, G. W., Yang, D., Zhang, Z., Zhou, C., Xu, Q., Wacker, D., Joseph, J. S., et al. (2013) · Nature · doi:10.1038/nature12393 · Cited by 379
Peptides Containing β-Amino Acid Patterns: Challenges and Successes in Medicinal Chemistry
Cabrele, C., Martinek, T. A., Reiser, O., & Berlicki, Ł. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010896 · Cited by 368
The structure and function of the glucagon‐like peptide‐1 receptor and its ligands
Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292
Advances in therapeutic peptides targeting G protein-coupled receptors
Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H., & Maguire, J. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0062-z · Cited by 275
Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators
Song, G., Yang, D., Wang, Y., de Graaf, C., Zhou, Q., Jiang, S., Liu, K., Cai, X., Dai, A., Lin, G., et al. (2017) · Nature · doi:10.1038/nature22378 · Cited by 241
Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Griffith, D. A., Edmonds, D. J., Fortin, J.-P., Kalgutkar, A. S., Kuzmiski, J. B., Loria, P. M., Saxena, A. R., Bagley, S. W., Buckeridge, C., Curto, J. M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01856 · Cited by 192
Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., et al. (2010) · Diabetes · doi:10.2337/db10-0689 · Cited by 143
Day, J. W., Gelfanov, V., Smiley, D., Carrington, P. E., Eiermann, G., Chicchi, G., Erion, M. D., Gidda, J., Thornberry, N. A., Tschöp, M. H., et al. (2012) · Peptide Science · doi:10.1002/bip.22072 · Cited by 133
Booe, J. M., Walker, C. S., Barwell, J., Kuteyi, G., Simms, J., Jamaluddin, M. A., Warner, M. L., Bill, R. M., Harris, P. W., Brimble, M. A., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.018 · Cited by 122
Allostery and biased agonism at class B G protein-coupled receptors
Wootten, D., Miller, L. J., Koole, C., Christopoulos, A., & Sexton, P. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00049 · Cited by 112
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00174 · Cited by 101
Liu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34
Glucagon‐like peptide‐1: modulator of β ‐cell dysfunction and death
Rondas, D., D'Hertog, W., Overbergh, L., & Mathieu, C. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12165 · Cited by 32
Go, E. J., Hwang, S.-M., Jo, H., Rahman, M. M., Park, J., Lee, J. Y., Jo, Y. Y., Lee, B.-G., Jung, Y., Berta, T., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01342-8 · Cited by 28
Thompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154229 · Cited by 19
“The V36A mutation in the GLP-1R has previously been shown to affect GLP-1 binding to the orthosteric binding site [35].”
BackgroundSun, L., Zheng, Z.-M., Shao, C.-S., Zhang, Z.-Y., Li, M.-W., Wang, L., Wang, H., Zhao, G.-H., & Wang, P. (2022) · Pharmaceuticals · doi:10.3390/ph15060740 · Cited by 17
“For the docking of GLP-1R and G1, according to the interaction analysis of the crystal structure of GLP-1R and GLP-1 [48], Leu32, Trp39, Asp67, Arg121, Leu123, Glu127, and Glu128 were selected as the active residues of the GLP-1 receptor, and Gln17, Ala18, Ala19, Lys20, Glu21, Phe22, Ile23, Trp25, and Leu26 were selec…”
Method
Metadata
- Authors
- Underwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R., & Reedtz-Runge, S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 285
- Issue
- 1
- Pages
- 723-730
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2078171783
- Cited by
- 295
- References
- 45
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.